LOS ANGELES, CA–(Marketwired – Jan 6, 2014) – Fresh Start Private Management, Inc. (OTCQB: CEYY), a leader in alcohol treatment and rehabilitation programs, announces the execution of a letter of understanding to acquire Trinity Rx Solutions and all of its formulas, including the naltrexone implant formula that is used to make the implant that the company currently has exclusive rights to in the U.S. and abroad.

With President Obama recently signing the Drug Quality and Security Act on November 27th, compounding laws now allow a new type of compounding pharmacy to be established, called an “outsourcing facility.” These facilities will fall under FDA oversight presumably resulting in greater patient safety. Fresh Start Private intends to start or acquire one of these facilities so that the company can take control over production and supply of the naltrexone implant once the complete formulation is acquired from Trinity. Currently, Fresh Start Private has exclusive rights to the implant used in its treatment program, but not ownership and knowledge of the exact formulation used to create it. The company would also retain compounding experts to assist with the facility start up and implant production.

If additional formulas controlled by Trinity are acquired, the company would begin producing and marketing those formulas to treat their respective healthcare issues. These other formulas include compounds for treating problems such as erectile dysfunction, smoking addiction, chronic pain, and more.

“This acquisition would be huge for our company in light of this new law. It also falls in line with our plans under the pending BioCorRx name,” said Kent Emry, CEO of Fresh Start Private Management, Inc. “But make no mistake. The alcohol program remains our top focus as we still have much to do, but this acquisition would improve that business model, while creating opportunities in other areas as our company continues to grow and mature in the future. We are not going to lose focus on our core product and that’s why we feel it’s important to own the formula outright and then make it in our own facility.”

About Fresh Start Private

Fresh Start Private Management, Inc. (OTCQB: CEYY) is an alcohol treatment and rehabilitation company on the leading edge of alcohol addiction treatment. The company has developed a highly effective program consisting of two main components used by various alcohol addiction clinics in the US. Clinic reports show that the treatment program has an 85% success rate with individuals that complete the program. The first component of the program consists of an outpatient implant procedure performed by a licensed physician that delivers targeted, therapeutic levels of the drug Naltrexone, an opiate antagonist that significantly reduces physical cravings for alcohol, into the body. The second component of the program developed by Fresh Start Private is a one on one coaching program specifically tailored for the treatment of alcoholism. For more information on CEYY, please visit www.freshstartprivate.com

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

Contact Information

Investor Relations Contact:
Maximum Performance Advisors, Inc.
858-381-4677